+

WO2002008451A3 - Assay for screening compounds for inducing drug metabolizing enzymes - Google Patents

Assay for screening compounds for inducing drug metabolizing enzymes Download PDF

Info

Publication number
WO2002008451A3
WO2002008451A3 PCT/EP2001/008129 EP0108129W WO0208451A3 WO 2002008451 A3 WO2002008451 A3 WO 2002008451A3 EP 0108129 W EP0108129 W EP 0108129W WO 0208451 A3 WO0208451 A3 WO 0208451A3
Authority
WO
WIPO (PCT)
Prior art keywords
assay
screening compounds
metabolizing enzymes
drug metabolizing
methods
Prior art date
Application number
PCT/EP2001/008129
Other languages
French (fr)
Other versions
WO2002008451A2 (en
Inventor
Ulrich Brinkmann
Leszek Wojnowski
Oliver Burk
Ilka Brehm
Original Assignee
Epidauros Biotechnologie Ag
Ulrich Brinkmann
Leszek Wojnowski
Oliver Burk
Ilka Brehm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidauros Biotechnologie Ag, Ulrich Brinkmann, Leszek Wojnowski, Oliver Burk, Ilka Brehm filed Critical Epidauros Biotechnologie Ag
Priority to AU2001285842A priority Critical patent/AU2001285842A1/en
Publication of WO2002008451A2 publication Critical patent/WO2002008451A2/en
Publication of WO2002008451A3 publication Critical patent/WO2002008451A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G01N2333/80—Cytochromes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Described are methods for screening inducers of genes involved in drug metabolization. In particular, an in vitro cell based assay is provided with cells derived from the cell line LS174T. Described are also methods for identifying and obtaining drugs for therapy of disorders related to the expression of the cytochrome P450 (CYP), gene family. Furthermore, kits suitable for such methods are provided.
PCT/EP2001/008129 2000-07-25 2001-07-13 Assay for screening compounds for inducing drug metabolizing enzymes WO2002008451A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001285842A AU2001285842A1 (en) 2000-07-25 2001-07-13 Assay for screening compounds for inducing drug metabolizing enzymes

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22056600P 2000-07-25 2000-07-25
US60/220,566 2000-07-25
US23109300P 2000-09-08 2000-09-08
US60/231,093 2000-09-08
EP00119365 2000-09-08
EP00119365.5 2000-09-08

Publications (2)

Publication Number Publication Date
WO2002008451A2 WO2002008451A2 (en) 2002-01-31
WO2002008451A3 true WO2002008451A3 (en) 2003-10-09

Family

ID=27223116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008129 WO2002008451A2 (en) 2000-07-25 2001-07-13 Assay for screening compounds for inducing drug metabolizing enzymes

Country Status (2)

Country Link
AU (1) AU2001285842A1 (en)
WO (1) WO2002008451A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP362898A0 (en) 1998-05-21 1998-06-11 University Of Sydney, The Xenobiotic induction of gene expression
AUPR116100A0 (en) 2000-11-01 2000-11-23 University Of Sydney, The P450 gene regulation
JP2005510205A (en) * 2001-04-12 2005-04-21 ゼノジェン コーポレイション Isolation and identification of mouse and human transcriptional regulatory elements associated with cytochrome expression
JP2003304896A (en) * 2002-04-15 2003-10-28 Yasushi Yamazoe Method for measuring human CYP3A inducibility
US7824912B2 (en) 2005-06-23 2010-11-02 Massachusetts Institute Of Technology Methods for ex vivo propagation of adult hepatic stem cells
EP3976116A4 (en) 2019-05-30 2023-08-23 490 Biotech, Inc. Lux expression in cells and methods of use
CN117110467B (en) * 2023-08-16 2024-08-20 苏州方昆医药科技有限公司 Pre-column chemical derivatization method of alcohol or phenol compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228236A (en) * 1978-05-15 1980-10-14 Northwestern University Process of producing carcinoembryonic antigen
WO1999048915A1 (en) * 1998-03-27 1999-09-30 Glaxo Group Limited Orphan nuclear receptor
WO1999061622A1 (en) * 1998-05-21 1999-12-02 The University Of Sydney Xenobiotic related induction of gene expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228236A (en) * 1978-05-15 1980-10-14 Northwestern University Process of producing carcinoembryonic antigen
WO1999048915A1 (en) * 1998-03-27 1999-09-30 Glaxo Group Limited Orphan nuclear receptor
WO1999061622A1 (en) * 1998-05-21 1999-12-02 The University Of Sydney Xenobiotic related induction of gene expression

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FANG W F ET AL: "EFFECTS OF CYCLO PHOSPHAMIDE AND POLY CYCLIC AROMATIC HYDRO CARBONS ON CELL GROWTH AND MIXED FUNCTION OXIDASE ACTIVITY IN A HUMAN COLON TUMOR CELL LINE", CANCER RESEARCH, vol. 42, no. 9, 1982, pages 3676 - 3681, XP009005520, ISSN: 0008-5472 *
HUANG L. ET AL.: "Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors", DRUG METABOL. DISPOS., vol. 29, May 2001 (2001-05-01), XP001145427 *
HUSTERT E. ET AL.: "Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4", DRUG METABOL. DISPOS., vol. 29, November 2001 (2001-11-01), pages 1454 - 1459, XP001145428 *
LEHMANN J M ET AL: "The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 102, no. 5, 1 September 1998 (1998-09-01), pages 1016 - 1023, XP000909297, ISSN: 0021-9738 *
OGG M S ET AL: "DEVELOPMENT OF AN IN VITRO REPORTER GENE ASSAY TO ASSESS XENOBIOTIC INDUCTION OF THE HUMAN CYP3A4 GENE", EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, vol. 22, no. 4, 1997, pages 311 - 313, XP000997639 *
VASQUEZ HERNAN ET AL: "Role of cytochrome P450 in DNA damage produced by treatment of colon cells with 1,2-dimethylhydrazine.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 18, no. 3, March 2001 (2001-03-01), pages 553 - 557, XP009005475, ISSN: 1019-6439 *
YAO DENGGAO ET AL: "Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: Implications for the development of drug resistance.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 294, no. 1, July 2000 (2000-07-01), pages 387 - 395, XP001135138, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
AU2001285842A1 (en) 2002-02-05
WO2002008451A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
Svensson et al. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin
Tsiouplis et al. TET-mediated epigenetic regulation in immune cell development and disease
Dai et al. CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database
Ozasa et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer
Oshikane et al. Structural basis of RNA-dependent recruitment of glutamine to the genetic code
WO2004029281A3 (en) Methods and compositions for rnai mediated inhibition of viral gene expression in mammals
Graham et al. Functional loss of ATRX and TERC activates alternative lengthening of telomeres (ALT) in LAPC4 prostate cancer cells
WO2001023592A3 (en) Methods for making recombinant proteins using apoptosis inhibitors
AU2003226608A1 (en) Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
EP1715062A3 (en) Method for detecting human papillomavirus mRNA
HUP0500161A2 (en) Methods to culture circovirus
Rysenkova et al. CRISPR/Cas9 nickase mediated targeting of urokinase receptor gene inhibits neuroblastoma cell proliferation
Becker et al. The heterotrimeric Thermus thermophilus Asp‐tRNAAsn amidotransferase can also generate Gln‐tRNAGln
Daldal et al. Mobile cytochrome c 2 and membrane-anchored cytochrome cy are both efficient electron donors to the cbb 3-and aa 3-type cytochrome c oxidases during respiratory growth of Rhodobacter sphaeroides
DE69333303T8 (en) EXOGEN CYTOCHROM P450 GENE CONTAINING IMMORTALIZED HUMAN CELL LINES
WO2002008451A3 (en) Assay for screening compounds for inducing drug metabolizing enzymes
von Eitzen et al. Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes
ATE275203T1 (en) IMMORTAL HUMAN CELL LINES CONTAINING EXOGENEOUS CYTOCHROME P-450 GENE
WO2003083051A3 (en) Multiplex standardized reverse transcriptase-polymerase chain reaction method for assessment of gene expression in small biological samples
AU2002303437A1 (en) Isolation of neural stem cells using gangliosides and other surface markers
Pène et al. A non-SUMOylated tax protein is still functional for NF-κB pathway activation
Forester et al. Regulation of eIF4E guides a unique translational program to control erythroid maturation
Peng et al. Role of DNA methylation on human CTSG in dermatomyositic myoideum
Coomes et al. Aryl hydrocarbon hydroxylase and 16α-hydroxylase in cultured human lymphocytes
Bose et al. Comparative error-free and error-prone translesion synthesis of N 2-2′-deoxyguanosine adducts formed by mitomycin C and its metabolite, 2, 7-diaminomitosene, in human cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载